Acazicolcept is a fusion protein commercialized by Alpine Immune Sciences, with a leading Phase II program in Systemic Lupus Erythematosus. According to Globaldata, it is involved in 4 clinical trials, of which 1 was completed, 1 is ongoing, 1 is planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Acazicolcept’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Acazicolcept is expected to reach an annual total of $74 mn by 2039 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Acazicolcept Overview

Acazicolcept is under development for the treatment of multiple sclerosis, arthritis, inflammatory bowel disease, hemophagocytic lymphohistiocytosis, sicca syndrome (sjogren), uveitis, type I diabetes, systemic lupus erythematosus. It acts by targeting inducible T-cell costimulator (ICOS) and T cell-specific surface glycoprotein CD28 (CD28). It is administered by intravenous or subcutaneous routes as an injection. The drug candidate is developed based on the variant immunoglobulin domain (vIgD) platform technology. It is a fusion protein, synthesized by combining vIgDs with antibody Fc domains.

It was also under development for psoriatic arthritis, graft versus host disease (GVHD) and rheumatoid arthritis.

Alpine Immune Sciences Overview

Alpine Immune Sciences (Alpine), formerly Nivalis Therapeutics Inc, is a pharmaceutical company. The company focuses on discovering and developing protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. It provides ALPN-101 and ALPN-303 for the treatment of based immunotherapies and immune synapses to treat cancer and autoimmune and inflammatory diseases. The company also provides ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer. It offers a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Alpine is headquartered in Seattle, Washington, the US.

The company reported revenues of (US Dollars) US$30.1 million for the fiscal year ended December 2022 (FY2022), an increase of 28.2% over FY2021. The operating loss of the company was US$58.2 million in FY2022, compared to an operating loss of US$49.9 million in FY2021. The net loss of the company was US$57.8 million in FY2022, compared to a net loss of US$50.3 million in FY2021.

For a complete picture of Acazicolcept’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 15 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.